By Rayyan Zafar an Honorary Research Assistant for Drug Science Can a ‘double standard’ in paediatric medicine provide a framework to restructure repressive medical cannabis policies? In 2019, a drug called Zolgensma came to market. This drug used a particularly innovative gene therapy technique to treat infants suffering with an extremely rare and catastrophic neuromuscular …
By Dr Anna Ross, an Honorary Research Assistant for Drug Science A reflection on the article “Coming Out”: Stigma, reflexivity and the drug researchers drug use. In 2015 I started a PhD in drug policy at the University of Edinburgh. It had been a long journey, and at the age of 34, with two …
By Dr Hannah Thurgur an Honorary Research Assistant for Drug Science As we welcome in the new year, Drug Science reflects on the year of 2020 for psilocybin research and celebrates these achievements. Here we focus on the use of psilocybin-assisted therapy in three different conditions to reflect the breadth of research currently taking place …
By Rayyan Zafar an Honorary Research Assistant for Drug Science It was 5 years ago in 2016 when Nick Clegg, the then deputy prime-minister of the United Kingdom became aware of a group of patients suffering with the severe nerve-wasting syndrome, multiple sclerosis, who were using cannabis to treat their condition. He heard accounts of …
What do horse riding, motorsports, base jumping, mountain climbing, storm chasing, and drug use have in common? They are of all course all potentially dangerous activities pursued for a thrill, a rush, and often a great deal of enjoyment. But in our modern-day prohibitionist culture, one of those things is not seen as being like …